Amphastar Pharmaceuticals, Inc. Total Liabilities and Equity
Amphastar Pharmaceuticals, Inc. (AMPH) had Total Liabilities and Equity of $1.74 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $1.74B.
- 2026-03-31: Liabilities and Equity $1.65B.
- 2025-12-31: Liabilities and Equity $1.63B.
- 2025-09-30: Liabilities and Equity $1.67B.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $1.74B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.65B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.63B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.67B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.62B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.63B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.58B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.55B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $1.49B 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $1.57B 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $1.51B 10-K · filed 2025-03-03 | |
| 2023-09-30 | $1.54B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $1.38B 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $773.66M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $741.99M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $726.70M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $723.72M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $716.24M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $671.53M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $651.68M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $665.75M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $645.74M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $631.24M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $613.72M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $600.06M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $572.83M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $586.97M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $585.64M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $601.30M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $544.72M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $513.56M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $480.64M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $451.65M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $449.78M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $451.07M 10-K · filed 2019-03-15 | $454.67M 10-K · filed 2018-03-14 |
| 2017-09-30 | $437.77M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $444.00M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $435.61M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $427.74M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $428.84M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $408.59M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $395.01M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $390.14M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $395.03M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $398.93M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $396.50M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $389.37M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $401.13M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $397.27M 10-Q · filed 2014-08-13 | |
| 2013-12-31 | $338.75M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |